Concord Biotech Ltd
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
- Market Cap ₹ 14,587 Cr.
- Current Price ₹ 1,396
- High / Low ₹ 1,725 / 900
- Stock P/E 47.3
- Book Value ₹ 146
- Dividend Yield 0.00 %
- ROCE 29.0 %
- ROE 21.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 9.57 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 512 | 616 | 713 | 853 | 1,017 | |
| 308 | 289 | 443 | 504 | 585 | |
| Operating Profit | 205 | 327 | 270 | 349 | 432 |
| OPM % | 40% | 53% | 38% | 41% | 42% |
| 32 | 14 | 23 | 37 | 37 | |
| Interest | 1 | 1 | 6 | 10 | 3 |
| Depreciation | 21 | 28 | 50 | 54 | 54 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 |
| Tax % | 21% | 25% | 26% | 25% | 25% |
| 169 | 235 | 175 | 240 | 308 | |
| EPS in Rs | 177.81 | 247.44 | 183.93 | 22.95 | 29.45 |
| Dividend Payout % | 22% | 0% | 3% | 0% | 30% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| TTM: | 30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 22% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 |
| Reserves | 761 | 990 | 1,094 | 1,280 | 1,516 |
| 52 | 86 | 62 | 32 | 10 | |
| 118 | 97 | 147 | 192 | 164 | |
| Total Liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 |
| 240 | 546 | 573 | 593 | 575 | |
| CWIP | 141 | 18 | 74 | 173 | 211 |
| Investments | 199 | 141 | 74 | 137 | 246 |
| 361 | 477 | 592 | 611 | 668 | |
| Total Assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 155 | 207 | 246 | 265 | ||
| -114 | -112 | -158 | -155 | ||
| -43 | -100 | -85 | -99 | ||
| Net Cash Flow | -1 | -4 | 3 | 12 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 131 | 105 | 119 | 117 | 125 |
| Inventory Days | 312 | 503 | 434 | 430 | 331 |
| Days Payable | 201 | 152 | 185 | 190 | 150 |
| Cash Conversion Cycle | 242 | 456 | 368 | 357 | 306 |
| Working Capital Days | 160 | 180 | 177 | 163 | 257 |
| ROCE % | 32% | 21% | 26% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
8m - Amendment), 2018, Please find the enclosed annual secretarial compliance report for the year ended March 31, 2024. Kindly take the above on records.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
48m - Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated May 21, 2024 to the Stock exchanges regarding Earning call in respect …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Of schedule III Part A (LODR) regulation 2015, Investor Presentation on financial results for the fourth quarter and year ended March 31, 2024 is enclosed. …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 May - Extracts of standalone and consolidated audited financial results for fourth quarter and year ended March 31, 2024 as published in Various Newspaper on May 24, …
- Correction In Dividend % Mentioned In The Outcome Of Board Meeting Held Today I.E. Thursday, May 23, 2024- Audited Financial Results For The Quarter And Financial Year Ended On March 31, 2024 23 May
Concalls
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptPPT
-
Sep 2023Transcript PPT
Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.